Cell and Gene Therapy Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030

Cell and Gene Therapy Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030

Cell and Gene Therapy Manufacturing Trends and Forecast

The future of the global cell and gene therapy manufacturing market looks promising with opportunities in the pharmaceutical & biotechnology company and academic & research institute markets. The global cell and gene therapy manufacturing market is expected to reach an estimated $19.1 billion by 2030 with a CAGR of 15.7% from 2024 to 2030. The major drivers for this market are rapid growth of the advanced therapy landscape, development in manufacturing technologies and processes, as well as, increasing prevalence of chronic diseases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cell and Gene Therapy Manufacturing by Segment

The study includes a forecast for the global cell and gene therapy manufacturing by indication, type, application, end use, and region.

Cell and Gene Therapy Manufacturing Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

• Oncology Diseases
• Cardiovascular Diseases
• Orthopedic Diseases
• Ophthalmology Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Others

Cell and Gene Therapy Manufacturing Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Cell Therapy
• Gene Therapy

Cell and Gene Therapy Manufacturing Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Clinical Manufacturing
• Commercial Manufacturing

Cell and Gene Therapy Manufacturing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell and Gene Therapy Manufacturing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cell and Gene Therapy Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cell and gene therapy manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cell and gene therapy manufacturing companies profiled in this report include-

• Lonza
• Catalent
• Thermo Fisher Scientific
• Charles River Laboratories
• WuXi AppTec
• Merck
• Takara Bio
• Oxford Biomedica
• Cell and Gene Therapy Catapult
• Genezen

Cell and Gene Therapy Manufacturing Market Insights

Lucintel forecasts that cell therapy is expected to witness the higher growth over the forecast period because the cell therapies can be used to treat cancer, autoimmune disorders, urinary tract infections, infectious diseases and other conditions, as well as, both the quantity of new products hitting the market and the quantity of clinical trials still in progress.

North America is expected to witness highest growth over the forecast period due to increasing involvement of organizations in gene and cell therapy research and product development, together with a sizable number of contract development firms in the area.

Features of the Global Cell and Gene Therapy Manufacturing Market

Market Size Estimates: Cell and gene therapy manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cell and gene therapy manufacturing market size by indication, type, application, end use, and region in terms of value ($B).

Regional Analysis: Cell and gene therapy manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different indication, type, application, end use, and regions for the cell and gene therapy manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cell and gene therapy manufacturing market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the cell and gene therapy manufacturing market size?

Answer: The global cell and gene therapy manufacturing market is expected to reach an estimated $19.1 billion by 2030.

Q2. What is the growth forecast for cell and gene therapy manufacturing market?

Answer: The global cell and gene therapy manufacturing market is expected to grow with a CAGR of 15.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cell and gene therapy manufacturing market?

Answer: The major drivers for this market are rapid growth of the advanced therapy landscape, development in manufacturing technologies and processes, as well as, increasing prevalence of chronic diseases.

Q4. What are the major segments for cell and gene therapy manufacturing market?

Answer: The future of the global cell and gene therapy manufacturing market looks promising with opportunities in the pharmaceutical & biotechnology company and academic & research institute markets.

Q5. Who are the key cell and gene therapy manufacturing market companies?

Answer: Some of the key cell and gene therapy manufacturing companies are as follows:

• Lonza
• Catalent
• Thermo Fisher Scientific
• Charles River Laboratories
• WuXi AppTec
• Merck
• Takara Bio
• Oxford Biomedica
• Cell and Gene Therapy Catapult
• Genezen

Q6. Which cell and gene therapy manufacturing market segment will be the largest in future?

Answer: Lucintel forecasts that cell therapy is expected to witness the higher growth over the forecast period because the cell therapies can be used to treat cancer, autoimmune disorders, urinary tract infections, infectious diseases and other conditions, as well as, both the quantity of new products hitting the market and the quantity of clinical trials still in progress.

Q7. In cell and gene therapy manufacturing market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing involvement of organizations in gene and cell therapy research and product development, together with a sizable number of contract development firms in the area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the cell and gene therapy manufacturing market by indication (oncology diseases, cardiovascular diseases, orthopedic diseases, ophthalmology diseases, central nervous system disorders, infectious diseases, and others), type (cell therapy and gene therapy), application (clinical manufacturing and commercial manufacturing), end use (pharmaceutical & biotechnology companies, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?